Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2010 May 13;24(3):207–211. doi: 10.1002/jcla.20334

Serum prolidase enzyme activity and its relation to histopathological findings in patients with non‐alcoholic steatohepatitis†

Mehmet Horoz 1, Mehmet Aslan 1,✉, Fusun F Bolukbas 2, Cengiz Bolukbas 2, Yasar Nazligul 2, Hakim Celik 3, Nurten Aksoy 3
PMCID: PMC6647739  PMID: 20486204

Abstract

The aim of this study was to investigate serum prolidase enzyme activity and to find out its association with liver biopsy specimens' histopathological findings in patients with nonalcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis. Thirty‐six patients with biopsy‐proven NASH and 29 healthy controls were enrolled. Serum prolidase enzyme activity was measured spectrophotometrically. Serum prolidase enzyme activity was significantly higher in patients with NASH thancontrols (P=0.016). A significant correlation was observed between serum prolidase enzyme activity and fibrosis score in patients with NASH (r=0.661, P<0.001). Serum prolidase activity seems to be correlated with the level of fibrosis. Monitoring serum prolidase activity may be a useful adjunctive tool in predicting liver fibrosis, especially in the absence of advanced fibrosis and other conditions, which may affect the interpretation of prolidase activity. J. Clin. Lab. Anal. 24:207–211, 2010. © 2009 Wiley‐Liss, Inc.

Keywords: fatty liver, liver biopsy, fibrosis, dipeptidases

†

NASH, non‐alcoholic steatohepatitis; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SD, standard deviation.

REFERENCES

  • 1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–438. [PubMed] [Google Scholar]
  • 2. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander‐Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–2474. [DOI] [PubMed] [Google Scholar]
  • 3. Day CP, James OF. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998;114:842–845. [DOI] [PubMed] [Google Scholar]
  • 4. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999;19:221–229. [DOI] [PubMed] [Google Scholar]
  • 5. Horoz M, Bolukbas C, Bolukbas FF, et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005;5:35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–1419. [DOI] [PubMed] [Google Scholar]
  • 7. Ernst P. Review article: The role of inflammation in the pathogenesis of gastric cancer. Alim Pharmacol Ther 1999;13:13–18. [DOI] [PubMed] [Google Scholar]
  • 8. Zanaboni G, Dyne KM, Rossi A, Monafo V, Cetta G. Prolidase deficiency: Biochemical study of erythrocyte and skin fibroblast prolidase activity in Italian patients. Haematologica 1994;79:13–18. [PubMed] [Google Scholar]
  • 9. Palka JA, Phang JM. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 1997;67:166–175. [DOI] [PubMed] [Google Scholar]
  • 10. Brosset B, Myara I, Fabre M, Lemonnier A. Plasma prolidase and prolinase activity in alcoholic liver disease. Clin Chim Acta 1988;175:291–295. [DOI] [PubMed] [Google Scholar]
  • 11. Myara I, Myara A, Mangeot M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity: A possible index of collagen catabolism in chronic liver disease. Clin Chem 1984;30:211–215. [PubMed] [Google Scholar]
  • 12. Kayadibi H, Gültepe M, Yasar B, et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non‐alcoholic fatty liver disease: A surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 2008. Nov 7. DOI: 10.1007/s10620-008-0535-0. [DOI] [PubMed] [Google Scholar]
  • 13. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: Application to imminodipeptiduria. Clin Chim Acta 1982;125:193–205. [DOI] [PubMed] [Google Scholar]
  • 14. Chinard FP. Photometric estimation of proline and ornithine. J Biol Chem 1952;199:91–95. [PubMed] [Google Scholar]
  • 15. Gabrielli GB, Capra F, Casaril M, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997;265:21–31. [DOI] [PubMed] [Google Scholar]
  • 16. James CH, Lindor KD. Outcome of patients admitted with complications after outpatient liver biopsies. Ann Intern Med 1993;118:96–98. [DOI] [PubMed] [Google Scholar]
  • 17. Rousselet MC, Michalak S, Dupré F, et al. Hepatitis Network 49: Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257–264. [DOI] [PubMed] [Google Scholar]
  • 18. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–526. [DOI] [PubMed] [Google Scholar]
  • 19. Imbert‐Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069–1075. [DOI] [PubMed] [Google Scholar]
  • 20. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL‐40, in patients with HCV‐associated liver disease. World J Gastroenterol 2005;11:476–481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Parés A, Deulofeu R, Giménez A, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996;24:1399–1403. [DOI] [PubMed] [Google Scholar]
  • 22. Patel K, Lajoie A, Heaton S, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003;18:253–257. [DOI] [PubMed] [Google Scholar]
  • 23. Weigand K, Zaugg PY, Frei A, Zimmermann A. Long‐term follow‐up of serum N‐terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984;4:835–838. [DOI] [PubMed] [Google Scholar]
  • 24. Fontana RJ, Goodman ZD, Dienstag JL, et al. HALT‐C Trial Group: Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789–798. [DOI] [PubMed] [Google Scholar]
  • 25. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non‐invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007;25:207–218. [DOI] [PubMed] [Google Scholar]
  • 26. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer‐based total serum protein glycomics. Nat Med 2004;10:429–434. [DOI] [PubMed] [Google Scholar]
  • 27. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 2006;55:403–408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Park GJ, Katelaris PH, Jones DB, et al. The C‐caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 2005;22:395–403. [DOI] [PubMed] [Google Scholar]
  • 29. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704–1713. [DOI] [PubMed] [Google Scholar]
  • 30. Yaron A, Naider F. Proline‐dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol 1993;28:31–81. [DOI] [PubMed] [Google Scholar]
  • 31. Aslan M, Nazligul Y, Horoz M, et al. Serum prolidase activity and oxidative status in Helicobacter pylori infection. Clin Biochem 2007;40:37–40. [DOI] [PubMed] [Google Scholar]
  • 32. Cakmak A, Zeyrek D, Atas A, Celik H, Aksoy N, Erel O. Serum prolidase activity and oxidative status in patients with bronchial asthma. J Clin Lab Anal 2009;23:132–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Bacon BR, Farahvash MJ, Janney CG, Neuschwander‐Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103–1109. [DOI] [PubMed] [Google Scholar]
  • 34. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286–1292. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES